Myasthenia Gravis News Home
Oct 14, 2024 — More than half of adults with generalized myasthenia gravis (gMG) show a clinically meaningful response to Ultomiris (ravulizumab-cwvz) within about two weeks of a first dose, according to a post-hoc analysis of clinical trial data.
News Archives - Myasthenia Gravis News
Myasthenia gravis (MG) cases increased gradually from 2000 to 2020 in Denmark, Finland, and Sweden, with the total number of cases and the number of newly diagnosed cases both rising, according to a population-based study.
Myasthenia Gravis News Forums – Connect with the MG Community
Post here if you’re seeking particular resources about myasthenia gravis, such as support groups, press releases, event info,…
Patients With gMG Saw Rapid Benefits With Soliris in Real-world …
Jun 23, 2022 — Soliris (eculizumab) safely and rapidly led to clinical benefits in people with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive, according to data from a small real-world U.S. study.
About Us - Myasthenia Gravis News
Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from our patient and caregiver columnists.
Dosing Begins in Study of Descartes-08 CAR T-Cell Therapy
Feb 2, 2023 — Patient dosing has begun in the first placebo-controlled clinical trial evaluating Cartesian Therapeutics’ Descartes-08, an investigational CAR T-cell therapy for people with generalized myasthenia gravis (gMG).
Vyvgart (efgartigimod) for myasthenia gravis
Jul 7, 2023 — Vyvgart (efgartigimod alfa-fcab) is an FDA-approved treatment for adults with generalized myasthenia gravis (gMG) who are positive for anti-AChR antibodies. It works by blocking FcRn, a protein that stabilizes IgG antibodies, and …
Types of myasthenia gravis – Myasthenia Gravis News
Jun 5, 2023 — All forms of myasthenia gravis are marked by muscle weakness and fatigue, but ocular myasthenia gravis is distinguished by the fact that weakness is limited to the muscles of the eyes and eyelids, whereas generalized myasthenia …
Myasthenia gravis: Causes, types, and more | Myasthenia Gravis …
Jul 13, 2023 — Myasthenia gravis is a neuromuscular disease characterized by weakness and fatigue that can affect muscles involved in voluntary movements.
Descartes-08 reduced gMG disease severity up to 1 year: Trial data
Jan 9, 2024 — Treatment with the experimental cell therapy Descartes-08 led to reductions in disease severity that were sustained out to one year for five of seven generalized myasthenia gravis (gMG) patients taking part in a Phase 2a clinical trial.